Stifel Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.
Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.